Similar articles

• Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.

  Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J; CATIE Study Investigators. Rosenheck RA, et al. Am J Psychiatry. 2006 Dec;163(12):2080-9. doi: 10.1176/ajp.2006.163.12.2080. Am J Psychiatry. 2006. PMID: 17151158 Clinical Trial.
• The NIMH-CATIE Schizophrenia Study: what did we learn?

  Lieberman JA, Stroup TS. Lieberman JA, et al. Am J Psychiatry. 2011 Aug;168(8):770-5. doi: 10.1176/appi.ajp.2011.11010039. Am J Psychiatry. 2011. PMID: 21813492 No abstract available.
• Outcomes, costs, and policy caution. A commentary on: the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

  Rosenheck RA. Rosenheck RA. Arch Gen Psychiatry. 2006 Oct;63(10):1074-6. doi: 10.1001/archpsyc.63.10.1074. Arch Gen Psychiatry. 2006. PMID: 17015809 No abstract available.
• Clinical trial-based cost-effectiveness analyses of antipsychotic use.

  Polsky D, Doshi JA, Bauer MS, Glick HA. Polsky D, et al. Am J Psychiatry. 2006 Dec;163(12):2047-56. doi: 10.1176/appi.ajp.163.12.2047. Am J Psychiatry. 2006. PMID: 17151153 Review.
• [Expensive but nevertheless cost effect? Pharmacoeconomics of atypical neuroleptics].

  Laux G, Günther W. Laux G, et al. Pharm Unserer Zeit. 2002;31(6):572-6. doi: 10.1002/1615-1003(200211)31:6<572::AID-PAUZ572>3.0.CO;2-D. Pharm Unserer Zeit. 2002. PMID: 12481515 Review. German. No abstract available.